Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(15%)
Results Posted
0%(0 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_3
1
8%
Ph phase_4
5
38%
Ph phase_2
3
23%
Ph not_applicable
2
15%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
5(41.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(4)
Terminated(2)
Other(4)

Detailed Status

Completed4
unknown4
Terminated2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 23 (25.0%)
Phase 31 (8.3%)
Phase 45 (41.7%)
N/A2 (16.7%)

Trials by Status

not_yet_recruiting18%
terminated215%
completed431%
unknown431%
recruiting215%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials

All 13 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
13